Researchers Discuss Evolution of Immunotherapy Approaches for Gynecologic Malignancies
Immunotherapy approaches are evolving for all types of gynecologic malignancies, including ovarian, cervical, and endometrial cancers.
Diagnosis & Disease Information
Pazopanib Maintenance Therapy Delays Relapse in Advanced Ovarian Cancer
Maintenance therapy with pazopanib after successful initial chemotherapy for advanced ovarian cancer prolongs time to relapse and PFS compared to placebo, found research presented at ASCO 2013.
Adjuvant Bevacizumab Well-Tolerated in Patients with Melanoma at High Risk of Recurrence
In patients with melaoma at high risk of recurrence, adjuvant bevacizumab is well tolerated and improves the disease-free interval, found research presented at ASCO 2013.
No Increased Cardiac Toxicity with Dual HER2 Blockade Therapy for Breast Cancer
Combined anti-HER2 therapy, with or without chemotherapy, does not increase the risk for cardiac toxicities compared to anti-HER2 monotherapy, found research presented at ASCO 2013.
Chemotherapy Drug Shortages Affect Patient Care, Impact Clinical Trials
A survey found that 83% of U.S. oncologists/hematologists reported a chemo drug shortage in the past 6 months, with 94% stating patient care was affected, according to data presented at ASCO 2013.
ADT Can Be Safely Reduced to 18 Months in Patients with Localized High-Risk Prostate Cancer
In men with localized high-risk prostate cancer, androgen-deprivation therapy can be safely reduced from 36 to 18 months, according to research presented at ASCO 2013.
Statins plus Aspirin Improve Overall Survival in Uterine Malignancies
Women with uterine malignancies who took statins and aspirin had an 84% reduction in mortality, while use of statins alone reduced mortality by 45%, according to data presented at ASCO 2013.
Anti-PD-L1 Agent Induces Durable Responses in Several Advanced Cancer Tumor Types
MPDL3280A produced durable responses in patients with locally advanced or metastatic lung cancer, melanoma, and renal, colorectal, and gastric cancers, some within days of treatment initiation, found research at ASCO 2013.
Nintedanib plus Docetaxel Prolongs PFS in Patients with Metastatic NSCLC
Nintedanib in combination with docetaxel significantly prolonged PFS for patients with metastatic NSCLC progressing after first-line chemotherapy regardless of histology, results from the LUME-Lung 1 trial presented at ASCO 2013 have found.
Number of Breast Cancer Gene Alterations Predicts Everolimus Benefit
The number of genetic alterations in tumors may predict which patients with breast cancer will benefit from adding everolimus to exemestane, found research presented at ASCO 2013.
- Loading...
Loading...
Loading... 
Loading...